A phase 1 study of the novel immunotoxin MT-5111 in patients with HER2+ tumors: Interim results.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Brian Andrew Van Tine, Joleen M. Hubbard, Monica M. Mita, Minal A. Barve, Erika P. Hamilton, Andrew J. Brenner, Frances Valdes, Daniel H. Ahn, Jason S. Starr, Joshua Pelham, Thomas Strack, Amy Yuet, Diana Yurewicz, Taunya J. Smith, Andres Machado, William Jeffery Edenfield, Aki Morikawa, Meena Okera, Nihal E. Abdulla, Zev A. Wainberg
Institutions: Washington University in St. Louis, Mayo Clinic, Cedars-Sinai Medical Center, Texas Oncology, Sarah Cannon, Tennessee Oncology, The University of Texas at San Antonio Health Science Center, Mays Cancer Center at UT Health San Antonio, University of Miami, Mayo Clinic Hospital, Molecular Templates (United States), Translational Research in Oncology, Prisma Health, University of Michigan, Ashland Bellefonte Cancer Center, Los Alamitos Medical Center, University of California, Los Angeles, Ronald Reagan UCLA Medical Center
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4286296383